Michael Plewe is Vice President – Medicinal Chemistry at Cullgen Inc., a company dedicated to the development of novel approaches for targeted protein degradation in oncology and immune disease. Before joining Cullgen in 2018, he was the Head of Chemistry at Arisan Therapeutics, a start-up focused on developing novel treatments for neglected viral diseases. Prior to Arisan, he was an Associate Research Fellow and project leader at Pfizer Inc. working in multiple therapeutic areas including oncology, ophthalmology, diabetes, and infectious diseases such as HIV. He was a medicinal chemist at Agouron and Vical, a gene therapy company. Dr. Plewe completed his postdoctoral training at the University of California at Irvine and earned his Ph. D. and Diploma in organic chemistry from the University of Konstanz in Germany.